Researchers at Harvard University have found a new genetic pathway that triggers fetal hemoglobin production in adults, opening promising therapeutic avenues for patients with sickle cell disease and beta-thalassemia. This newly discovered pathway operates entirely independently of the target genes in currently approved gene therapies.
- Landmark gene discovery to reactivate fetal hemoglobin
- Molecular repression mechanism and laboratory editing trials
- Qualitative integration with current therapies and drug development prospects
- Frequently asked questions
Landmark gene discovery to reactivate fetal hemoglobin
A joint scientific team from Boston Children’s Hospital, the Dana-Farber Cancer Institute, and the Broad Institute of Harvard and MIT has achieved a major medical breakthrough by discovering a previously unknown genetic pathway that activates fetal hemoglobin production in adults, thereby opening a promising and unprecedented therapeutic front to combat sickle cell disease and beta-thalassemia. Published Wednesday in the prestigious scientific journal Nature, the study identifies a precise regulatory axis known as BACH2-NRF2, which operates through a mechanism completely independent of the BCL11A gene targeted by currently licensed gene therapies.
Led by Dr. Vijay Sankaran, this exceptional research drew on genome-wide association study data from more than 28,000 individuals of diverse ancestral origins, including European, African, and Asian groups. Extensive analyses identified 91 genetic associations distributed across 12 chromosomal regions, among which emerged one of the strongest new genomic signals pointing directly to the BACH2 gene, a transcription factor historically linked to autoimmune diseases and allergies, with no prior connection whatsoever to the regulation of blood hemoglobin production.
Molecular repression mechanism and laboratory editing trials
Biological experiments revealed that the BACH2 gene acts as a molecular brake that halts fetal hemoglobin production at later developmental stages. Under normal conditions, the BACH2 protein settles on the genetic promoter of the gamma-globin chain, preventing the activation protein NRF2 from reaching it. When this gene is inhibited or its levels are reduced within cells, the activator is able to bind to the regulatory elements of the gamma-globin gene, restarting fetal hemoglobin production with high efficiency.
In laboratory experiments conducted on hematopoietic stem cells, inhibition of the BACH2 protein—whether via small interfering RNA silencing technology, targeted base editing, or the use of small molecule inhibitors—significantly elevated fetal hemoglobin levels without causing any disruption or defect in the normal maturation pathway of red blood cells.
Qualitative integration with current therapies and drug development prospects
This discovery gains exceptional clinical value given that the BACH2 axis operates via a parallel pathway completely separate from the BCL11A gene targeted by the revolutionary gene editing technology Casgevy, officially approved in December 2023 and co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics. Laboratory experiments showed that the simultaneous inhibition of both genes produces a cumulative and multiplied increase in the gene expression levels of the gamma-globin protein, indicating that targeting both pathways together could provide therapeutic benefits far exceeding those achieved by individual interventions.
Dr. Sankaran commented: “For nearly 20 years, human genetics research has led us to discover BCL11A and paved the way for the emergence of the first gene therapies, and what is exciting about our study today is that the exact same genetic methodology continues to uncover entirely new pathways to reactivate fetal hemoglobin.” The researchers hinted that certain small drug molecules already in development to treat sickle cell anemia may target the BACH2 pathway, and the team plans to conduct future clinical trials to confirm the complete safety of this pathway in patients and explore direct drug combination approaches.
Frequently asked questions
Question: What is the new genetic pathway discovered by Harvard scientists to treat sickle cell anemia?
Answer: Scientists discovered the BACH2-NRF2 axis, a genetic pathway that regulates the repression and activation of fetal hemoglobin production in blood cells.
Question: How does this new discovery differ from the approved gene therapy Casgevy?
Answer: The new pathway operates via a mechanism separate from the BCL11A gene targeted in Casgevy, allowing them to potentially be combined to multiply the production of life-saving hemoglobin.
Question: Does the discovery open the door to developing traditional chemical drugs instead of complex genetic editing?
Answer: Yes, the researchers noted that inhibiting this gene can be achieved via small drug molecules, which could provide affordable pill-based treatments in the future.
